Corrigendum to “Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials” volume 72, 102621

Benzer Materyaller

• Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction
  Yazar:: Geert D'Haens, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-06-01)
• The Impact of Mesalazine Pill Burden on Compliance in Inflammatory Bowel Disease Patients
  Yazar:: Julien Kirchgesner, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-01-01)
• MESALAZINE PLACE IN THERAPY OF ULCERATIVE COLITIS
  Yazar:: I. G. Bakulin, ve diğerleri
  Baskı/Yayın Bilgisi: (2017-11-01)
• Mesalazine use tactics in the ulcerative colitis patients
  Yazar:: A. V. Korolev, ve diğerleri
  Baskı/Yayın Bilgisi: (2013-03-01)
• Efficacy of mesalazine at ulcerative colitis with nutritional failure
  Yazar:: A. V. Korolyov, ve diğerleri
  Baskı/Yayın Bilgisi: (2015-03-01)